Projects & Grants




Use of new biomarkers in the diagnosis of acute coronary syndrome; their comparison with routinely used biomarkers
Project IdSGS13/LF/2019-2020
Main solverRNDr. Radka Šigutová
Period1/2019 - 12/2020
ProviderSpecifický VŠ výzkum
Statesolved
AnotationThe aim of the project is to compare and establish the clinical relevance of new biomarkers (Heart fatty acid binding protein; H-FABP3, growth differentiation factor 15; GDF-15 and Cardiac myosin binding protein-C; cMyBP-C) compared to routinely used biochemical parameters for diagnosing acute coronary syndrome (ACS). ACS presents a significant risk of mortality and morbidity worldwide. New biomarkers of ACS can play a crucial role in the diagnosis of acute cardiac ischaemia, helping to stratify patients' risk and thus contributing to a more timely and more accurate decision of the physician on further treatment and monitoring of the patient. For their use in clinical practice, it is more than necessary to carry out practical studies to show their contribution to setting up a more appropriate and faster therapy for patients with ACS. A retrospective study of the diagnoses of the patients will be performed at the Department of Clinical Biochemistry, in which were determined the cardiomarkers hs TNI and NT-proBNP. In these patients there will be realized anonymous collection of aliquots of plasma samples, which will be frozen to -70 ° C until analysis (ELISA assay of all three new biomarkers). Immunochemical determination of new biomarkers will take place at the Institute of Laboratory Diagnostics, Department of Clinical Biochemistry, University Hospital Ostrava using DsX ELISA automate. The results of this study will be useful for early diagnosis of patients with ACS, and may also contribute to more accurate physician decisions about further treatment and monitoring of the patient.